A monoclonal antibody targeting CD302 (MMRI−20) has been shown to induce antibody−dependent cellular cytotoxicity (ADCC) by recruiting effector cells such as natural killer cells or macrophages to kill AML cells (16). Here, CD302 is linked to acute myeloid leukemia.